Bulldog Investors’s Bellevue Life Sciences Acquisition Corp. Rights BLACR Stock Holding History

Bulldog Investors’s Portfolio BLACR Stock Details BLACR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-15,460	Closed	-$1.61K	–	185
2024 Q3	$1.61K	Sell	15,460 -4,180	-21%	-$554	﹤0.01%	127
2024 Q2	$1.96K	Hold	19,640	–	–	﹤0.01%	129
2024 Q1	$2.67K	Buy	+19,640	New	+$3K	﹤0.01%	143
2023 Q4	–	Sell	-21,620	Closed	-$4.97K	–	189
2023 Q3	$4.97K	Hold	21,620	–	–	﹤0.01%	157
2023 Q2	$4.13K	Sell	21,620 -2,044	-9%	-$356	﹤0.01%	170
2023 Q1	$3.55K	Buy	+23,664	New	+$3.68K	﹤0.01%	215

Other funds holding BLACR

HCM

Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.27% 1-Year Est. Return

HCI

Harraden Circle Investments New York $499M AUM 19.71% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.02% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return

ASM

ATW SPAC Management New York $79.2M AUM 10.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return

Walleye Trading New York $87.6B AUM 68.17% 1-Year Est. Return

Bulldog Investors's BLACR Position: Q4 2024 in Review

Bulldog Investors sold out of Bellevue Life Sciences Acquisition Corp. Rights (BLACR) in Q4 2024, closing a stake of 15,460 shares — an estimated $1.61K sold.

Bulldog Investors first reported a position in BLACR in Q1 2023 and held it in 6 quarters. The position peaked at $4.97K in Q3 2023. 28 funds tracked by Wall St. Rank hold BLACR as of Q4 2024.

Bulldog Investors reported no remaining Bellevue Life Sciences Acquisition Corp. Rights position as of Q4 2024 after selling out during the quarter.
Bulldog Investors sold 15,460 Bellevue Life Sciences Acquisition Corp. Rights shares in Q4 2024, an estimated $1.61K.
Bulldog Investors first reported a position in Bellevue Life Sciences Acquisition Corp. Rights in Q1 2023 and held it in 6 quarters.
Bulldog Investors's Bellevue Life Sciences Acquisition Corp. Rights position peaked at $4.97K in Q3 2023.
28 funds tracked by Wall St. Rank held Bellevue Life Sciences Acquisition Corp. Rights as of Q4 2024.

Based on Bulldog Investors's 13F filing for Q4 2024, filed 14 Feb 2025.